Various classes of FSCN1 inhibitors have been identified and tested in different cancer models: migrastatin derivatives such as macroketone, which bind at the actin-interacting domain of FSCN1 [57]; thiazole derivatives designed for FSCN1 inhibition that also exhibit antiangiogenic properties [65]; and miRNA-145, shown to downregulate FSCN1 expression through direct interaction with its 3′-UTR [66]. This evidence concerns the gene FSCN1 and cancer.